AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02772978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
Trial: NCT00046553
Drug: RU-486 (Mifepristone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02071888
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutaminase inhibitor
Trial: NCT01997515
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (placebo) will receive the same amount of saline.
Trial: NCT03647228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator calculated volume to match active comparator inhaled or nebulized.
Trial: NCT03464526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily, oral
Trial: NCT03616899
Drug: KPI-121 Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 Ophthalmic Suspension
Trial: NCT03616899
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle for KPI-121 0.25% ophthalmic suspension
Trial: NCT01983358
Drug: JPI-289
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP-1 inhibitor
Trial: NCT00939913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
Trial: NCT01053507
Drug: sumatriptan/naproxen sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Trial: NCT01053507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
Trial: NCT01047007
Drug: 5-FU 1000 mg/m^2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
Trial: NCT00429143
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
Trial: NCT00976144
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
Trial: NCT01989221
Drug: Sancuso®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
Trial: NCT00059202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Urso
Trial: NCT02664116
Drug: Diclofenac postassium powder for oral solution and placebo injection
RxNorm normalized name: diclofenac Powder for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
Trial: NCT02664116
Drug: Ketorolac intramuscular injection and placebo oral solution
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
Trial: NCT01201928
Drug: Comparator administered in parent trial
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
Trial: NCT01201928
Drug: Technosphere Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
Trial: NCT02955888
Drug: PBI4050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT02955888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT03886948
Drug: LY3074828
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT01290926
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib 600mg/day capecitabine 1250 mg/m²/day
Trial: NCT01125410
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vaginal cream, 2%, once daily for 7 days
Trial: NCT00566046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
Trial: NCT03084029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 international units
Trial: NCT00786487
Drug: 20% lipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml/min for 6 hours
Trial: NCT03877289
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin.
Trial: NCT04396990
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Trial: NCT04396990
Drug: Topical Prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care topical drop treatment
Trial: NCT04611750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given for 14 days
Trial: NCT01466348
Drug: Paracetamol and Caffeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg and caffeine 130 mg
Trial: NCT02647086
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytochrome P450 substrate
Trial: NCT00049101
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00049101
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01791842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00183092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg by mouth three times a day
Trial: NCT00966602
Drug: VX-809 & VX-770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
Trial: NCT00966602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03676322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to M5049.
Trial: NCT01995084
Drug: [F-18]HX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
Trial: NCT00878007
Drug: Intermittent screening and treatment for malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
Trial: NCT00605475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
Trial: NCT02717988
Drug: SKI-O-703 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKI-O-703 25 mg capsule or 200 mg capsule without excipient
Trial: NCT02717988
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 180 mg capsule filled with microcrystalline cellulose
Trial: NCT04311112
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00094926
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo IM injections every 2wks for 52wks
Trial: NCT04713410
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
Trial: NCT03033680
Drug: [F-18]PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET radiopharmaceutical
Trial: NCT02357901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
Trial: NCT04206631
Drug: Doxycycline Capsule
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
Trial: NCT03774771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT00074139
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00074139
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03125980
Drug: capecitabine plus oxaliplatin before and after surgery
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~1. Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~2. Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~3. Repeat every 3 weeks (Q3W)
Trial: NCT00769288
Drug: 2'-F-ara-deoxyuridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00400400
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
Trial: NCT02871349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
Trial: NCT04199585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, single dose, orally
Trial: NCT00196677
Drug: Vitamins, minerals and medical herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01154491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
Trial: NCT01694433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g daily BID
Trial: NCT03071861
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of normal saline, IV, given at less than 24 hours of age
Trial: NCT03771040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215057
Drug: topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical anesthetic drops and Group 2
Trial: NCT00344175
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02186782
Drug: Clomiphene citrate and Estradiol
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
Trial: NCT02737319
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg of rosuvastatin before angioplasty
Trial: NCT00400400
Drug: Placebo to mycophenolate sodium
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to mycophenolate sodium matching tablets.
Trial: NCT00838058
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 250mg tablet, once in the morning in fasted state
Trial: NCT00838058
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x250 mg tablets, once in the morning, in fasted state
Trial: NCT00838058
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x250mg tablets, once in the morning, in fasted state
Trial: NCT00838058
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x250mg tab, once in the morning, after being fed a high fat meal
Trial: NCT00838058
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
Trial: NCT00838058
Drug: CE-224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x125 mg IR once in the morning after being fed a high fat meal
Trial: NCT03371199
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch tablets
Trial: NCT00838058
Drug: CE 224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
Trial: NCT00838058
Drug: CE 224,535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
Trial: NCT00400400
Drug: Placebo to mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo to mycophenolate mofetil matching capsules.
Trial: NCT01497977
Drug: phytoestrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
Trial: NCT00869635
Drug: S-1 Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
Trial: NCT04461015
Drug: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clamp study with insulin infused at 0.4 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.8 mU/Kg/min
Trial: NCT04461015
Drug: 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clamp study with insulin infused at 0.8 mU/Kg/min, followed by a 2 week withdrawal period followed by a clamp study with insulin infused at 0.4 mU/Kg/min
Trial: NCT03001661
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
Trial: NCT00413660
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 blinded tablets administered BID
Trial: NCT01984775
Drug: GSK2894512 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% \[5 milligram (mg)/gram (g)\], 1% \[10 mg/g\], and 2% \[20 mg/g\]).
Trial: NCT01984775
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream does not contain any active pharmaceutical ingredient.
Trial: NCT00413660
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01458301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
Trial: NCT02229786
Drug: Buscopan® plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229786
Drug: Buscopan®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03369665
Drug: Mavenclad®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
Trial: NCT01664247
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered s.c. (under the skin) once daily. Dose individually adjusted.
Trial: NCT01349205
Drug: Caffeine and sodium Benzoate 10 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, 10mg/kg, IVP, 1 time
Trial: NCT01349205
Drug: Caffeine and Sodium Benzoate 20 mg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, 20 mg/kg, IVP, 1 time
Trial: NCT01349205
Drug: 0.9 NS Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, 0-10 ml, IVP, 1 time
Trial: NCT03369015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
Trial: NCT01212471
Drug: Bromfenac Ophthalmic Solution A
RxNorm normalized name: bromfenac Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT01212471
Drug: Bromfenac Ophthalmic Solution B
RxNorm normalized name: bromfenac Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT01212471
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT03318315
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion adjuvant.
Trial: NCT00343200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
Trial: NCT00510809
Drug: Policosanol
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg daily
Trial: NCT00510809
Drug: Policosanol Plus Already In Use Statin Therapy
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg daily Statin Therapy
Trial: NCT02167945
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use
Trial: NCT02167945
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use
Trial: NCT00375427
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.